Cargando…
Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis.
BACKGROUND: Several RT-qPCR kits are available for SARS-CoV-2 diagnosis, some of them with Emergency Use Authorization (EUA) by FDA, but most of them lacking of proper evaluation studies due to covid19 emergency. OBJECTIVE: We evaluated Viasure RT-qPCR kit (CerTest Biotec, Spain) for SARS-CoV-2 diag...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673214/ https://www.ncbi.nlm.nih.gov/pubmed/33278737 http://dx.doi.org/10.1016/j.virol.2020.10.010 |
_version_ | 1783611279383986176 |
---|---|
author | Freire-Paspuel, Byron Vega-Mariño, Patricio Velez, Alberto Cruz, Marilyn Perez, Franklin Garcia-Bereguiain, Miguel Angel |
author_facet | Freire-Paspuel, Byron Vega-Mariño, Patricio Velez, Alberto Cruz, Marilyn Perez, Franklin Garcia-Bereguiain, Miguel Angel |
author_sort | Freire-Paspuel, Byron |
collection | PubMed |
description | BACKGROUND: Several RT-qPCR kits are available for SARS-CoV-2 diagnosis, some of them with Emergency Use Authorization (EUA) by FDA, but most of them lacking of proper evaluation studies due to covid19 emergency. OBJECTIVE: We evaluated Viasure RT-qPCR kit (CerTest Biotec, Spain) for SARS-CoV-2 diagnosis using FDA EUA 2019-nCoV CDC kit (IDT, USA) as a gold standard. RESULTS: Although we found the lack of RNA quality control probe as the main limitation for the Viasure kit, the sensitivity was 91.9% and the specificity was 100%. The limit of detection (LOD) was 2000 copies/mL and 1000 copies/mL for Viasure and IDT kits, respectively. CONCLUSIONS: Viasure RT-qPCR kit is a reliable tool for SARS-CoV-2 diagnosis but improvement of an alternative RT-qPCR reaction for RNA extraction quality control as RNaseP is recommended. |
format | Online Article Text |
id | pubmed-7673214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76732142020-11-19 Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis. Freire-Paspuel, Byron Vega-Mariño, Patricio Velez, Alberto Cruz, Marilyn Perez, Franklin Garcia-Bereguiain, Miguel Angel Virology Article BACKGROUND: Several RT-qPCR kits are available for SARS-CoV-2 diagnosis, some of them with Emergency Use Authorization (EUA) by FDA, but most of them lacking of proper evaluation studies due to covid19 emergency. OBJECTIVE: We evaluated Viasure RT-qPCR kit (CerTest Biotec, Spain) for SARS-CoV-2 diagnosis using FDA EUA 2019-nCoV CDC kit (IDT, USA) as a gold standard. RESULTS: Although we found the lack of RNA quality control probe as the main limitation for the Viasure kit, the sensitivity was 91.9% and the specificity was 100%. The limit of detection (LOD) was 2000 copies/mL and 1000 copies/mL for Viasure and IDT kits, respectively. CONCLUSIONS: Viasure RT-qPCR kit is a reliable tool for SARS-CoV-2 diagnosis but improvement of an alternative RT-qPCR reaction for RNA extraction quality control as RNaseP is recommended. Elsevier Inc. 2021-01-15 2020-11-18 /pmc/articles/PMC7673214/ /pubmed/33278737 http://dx.doi.org/10.1016/j.virol.2020.10.010 Text en © 2020 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Freire-Paspuel, Byron Vega-Mariño, Patricio Velez, Alberto Cruz, Marilyn Perez, Franklin Garcia-Bereguiain, Miguel Angel Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis. |
title | Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis. |
title_full | Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis. |
title_fullStr | Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis. |
title_full_unstemmed | Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis. |
title_short | Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis. |
title_sort | analytical and clinical comparison of viasure (certest biotec) and 2019-ncov cdc (idt) rt-qpcr kits for sars-cov2 diagnosis. |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673214/ https://www.ncbi.nlm.nih.gov/pubmed/33278737 http://dx.doi.org/10.1016/j.virol.2020.10.010 |
work_keys_str_mv | AT freirepaspuelbyron analyticalandclinicalcomparisonofviasurecertestbiotecand2019ncovcdcidtrtqpcrkitsforsarscov2diagnosis AT vegamarinopatricio analyticalandclinicalcomparisonofviasurecertestbiotecand2019ncovcdcidtrtqpcrkitsforsarscov2diagnosis AT velezalberto analyticalandclinicalcomparisonofviasurecertestbiotecand2019ncovcdcidtrtqpcrkitsforsarscov2diagnosis AT cruzmarilyn analyticalandclinicalcomparisonofviasurecertestbiotecand2019ncovcdcidtrtqpcrkitsforsarscov2diagnosis AT perezfranklin analyticalandclinicalcomparisonofviasurecertestbiotecand2019ncovcdcidtrtqpcrkitsforsarscov2diagnosis AT garciabereguiainmiguelangel analyticalandclinicalcomparisonofviasurecertestbiotecand2019ncovcdcidtrtqpcrkitsforsarscov2diagnosis |